Gene Therapy Clinical Trial Services Market - By Services (Clinical Trial Design & Planning, Supply & Logistics, Regulatory, Data Management & Biostatistics), Therapeutic Areas (Oncology, Musculoskeletal, CVD), End-user - Global Forecast (2024

Description

Global Gene Therapy Clinical Trial Services Market will record 9.2% CAGR during 2024-2032, driven by positive regulatory initiatives and growing investments in R&D.

The growing incidence of chronic ailments acts as a major growth driver in the market. According to WHO, noncommunicable diseases (NCDs) kill 41 million individuals annually, contributing to 74% of all deaths. Diseases, including cancer, cardiovascular disorders, and neurodegenerative conditions, have placed substantial burden on healthcare systems. Traditional treatment procedures offer superficial care or manage symptoms without addressing the underlying genetic causes of these diseases. Gene therapy provides an appealing approach to tackle NCDs at their roots, offering curative or disease-modifying treatments. As the incidence of chronic health diseases continues to surge globally, there is rising demand for innovative therapeutic solutions, thereby propelling market growth.

Global gene therapy clinical trial services industry is classified based on services, therapeutic areas, end-user, and region.

Supply chain & logistics service segment share will grow rapidly through 2032, as the complex nature of gene-based treatments, including personalized therapies and viral vectors, makes meticulous planning and execution of supply chain operations mandatory. From sourcing raw materials and managing cold chain logistics to ensuring on-time delivery of investigational products, these services are essential to conduct of gene therapy clinical trials. The service providers offer comprehensive supply chain solutions tailored to the specific demand of each trial, thereby allowing efficient and compliant trials.

Gene therapy clinical trial services market share from musculoskeletal disorders segment will witness a decent surge during 2024-2032, as these conditions, including degenerative joint diseases, muscular dystrophies, and bone disorders, impose a heavy burden on healthcare systems globally. Gene therapy holds a lot of potential in acknowledging the underlying genetic defects associated with these disorders, providing the possibility of disease modification and functional improvement. Clinical trials, that are focused on gene-based interventions for musculoskeletal disorders are thus gaining momentum, inducing demand for specialized services tailored to the unique requirements of these trials.

Europe gene therapy clinical trial services industry size will grow rapidly through 2032, owing to the robust healthcare infrastructure, stringent regulatory framework, and growing investments in R&D . Nations such as the United Kingdom, Germany, France, and Switzerland are leading gene therapy research and innovation, harboring a vibrant ecosystem for clinical trial services. Moreover, collaborations between academic institutions, biopharmaceutical companies, and contract research organizations (CROs) are fueling the advancement of gene therapy clinical trials in the region. With a favorable regulatory environment and a large number of gene therapy candidates, Europe market is set to witness substantial growth.

Product Code: 9312

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Globalization of clinical trials
  - 3.2.1.2 Increasing prevalence of genetic and chronic diseases
  - 3.2.1.3 Growing advancements in gene therapy technologies
  - 3.2.1.4 Expanded applications in oncology and rare diseases
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory challenges
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Services, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Clinical trial design & planning
5.3 Supply & logistics services
5.4 Regulatory services
5.5 Data management & biostatistics
5.6 Site management & monitoring
5.7 Other services

Chapter 6 Market Estimates and Forecast, By Service, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Oncology
6.3 Hematology
6.4 Endocrine/ metabolic disorders
6.5 Musculoskeletal
6.6 Cardiovascular diseases (CVD)
6.7 Neurology disorders
6.8 Infectious disease
6.9 Ophthalmology
6.10 Immunology
6.11 Other therapeutic areas

Chapter 7 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Pharmaceutical & biotechnology companies
7.3 Contract research organizations (CROs)
7.4 Academic and research institutes
7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

9.1 Almac Group
9.2 Catalent Biologics
9.3 Charles River Laboratories International, Inc.
9.4 ICON plc
9.5 IQVIA Biotech
9.6 Labcorp Drug Development
9.7 Medpace Holdings, Inc.
9.8 Novotech
9.9 Parexel International (MA) Corporation
9.10 Precision Medicine Group LLC
9.11 Sharp Services, LLC
9.12 Thermo Fisher Scientific Inc.
9.13 Worldwide Clinical Trials

Gene Therapy Clinical Trial Services Market - By Services (Clinical Trial Design & Planning, Supply & Logistics, Regulatory, Data Management & Biostatistics), Therapeutic Areas (Oncology, Musculoskeletal, CVD), End-user - Global Forecast (2024 - 2032)